The Silverstein Foundation: Accelerating research in Parkinson's with GBA
New York, USA
Joined March 2017
- Tweets427
- Following640
- Followers477
- Likes400
Thank you for having us @ZivGanOr! Excited to begin.
Now at the #GBA1Meeting pre-meeting of the @silversteinFNDN, which sponsors 12 fellows around the world who study GBA1.
The first in-person meeting of The Silverstein Foundation Fellows. All gathered at the GBA1 meeting at @TheNeuro_MNI. Excited to hear updates from all of our fellows. #cureGBAPD
Silverstein FNDN retweeted
The Silverstein Foundation @silversteinFNDN launches a program of 2-year, post-doctoral fellowships to fund 11 scientists working on novel research for #Parkinsons in GBA mutation carriers
businesswire.com/news/home/2…
Silverstein FNDN retweeted
One of the best ways to invest in research is to invest in people. I'm very grateful that the @silversteinFNDN have selected us as one of the centers to receive funding for a 2-years fellowship to study GBA1. Please contact me if you are interested.
businesswire.com/news/home/2…
We are excited to announce our new Post-Doctoral Fellowship Program today. #cureGBAPD businesswire.com/news/home/2…
Silverstein FNDN retweeted
New clinical study registered: @ScottNYSCF & colleagues at the @nyscf & @silversteinFNDN are seeking skin biopsies &/or blood cells from people with GBA-associated #Parkinsons for drug discovery projects
clinicaltrials.gov/ct2/show/…
Proud of this announcement and our partnership with @VanquaBio
Vanqua Bio is pleased to announce we have closed an $85 million Series B financing round, led by Omega Funds. We’re excited to help usher in a new era of hope for patients living with neurodegenerative disorders.
Learn more: globenewswire.com/news-relea… #Biopharma
"Vanqua Bio is helping usher in a new era of hope for people living with neurodegenerative disorders.” - Jim Sullivan, PhD, Co-founder and CEO of Vanqua Bio
Silverstein FNDN retweeted
More #Funding & #Grants
@dnanudge completion of $60M #SeriesA #Investment Led by #VenturaCapital
@OxBioDynamics awarded #FNIH #grant for applications for to apply #EpiSwitch® #ImmuneHealth test
#Cancer #Therapies
@silversteinFNDN funding for #AcureXTherapeutics
#Parkinsons
We are proud to announce another transformative grant in Parkinson’s with GBA globenewswire.com/news-relea…
Today is #GivingTuesday a global generosity movement for giving to the causes you care most about. Help us beat Parkinson's #Parkinsons #cureGBA silversteinfoundation.org/do…
Silverstein FNDN retweeted
Just a few of the programs that will forever change PD (& more) in the decade to come...
@silversteinFNDN
@CureParkinsonsT's LCT
@TheNeuro_MNI's OS
@C_R_A_N_I_A
@thesgconline
ASAP (needs @ @ELeap29 ;)
CCBP (ditto)
@LashuelLab
@cziscience
@AllenInstitute
@predictPD
@pdgenetics
The @MichaelJFoxOrg featured #PrevailTherapeutics in a blog post announcing recruitment for the PROPEL trial, a #genetherapy clinical trial for PD patients with a GBA mutation. Read the blog here: bit.ly/36lQyyf Learn more about the trial here: bit.ly/2qYnFrT
Last week the @silversteinFNDN held it’s 3rd annual Scientific Advisory Board meeting, focusing on 8 different therapeutic approaches that we have funded. In all, we have made 32 grants since our launch in 2017. We will put our 3rd drug into human trials in mid-Nov. #cureGBA
Silverstein FNDN retweeted
Interesting new clinical trial registered by @PPRI__ with support from @MichaelJFoxOrg & @silversteinFNDN to analyze the molecular & clinical mechanisms of the relationship between the GBA mutations & #Parkinsons
clinicaltrials.gov/ct2/show/…
Silverstein FNDN retweeted
This is a @silversteinFNDN-supported project, which we have previously discussed on the SoPD website:
scienceofparkinsons.com/2019…
Silverstein FNDN retweeted
New company Surmount Bio has been set up to explore & develop S-181 further. Backed by @silversteinFNDN-associated @OrbiMed - Wow, a lot happening in the GBA-#Parkinsons world! Prevail, Surmount,... what next?
Silverstein FNDN retweeted
We are making some bold assumptions with the current stock of GBA-#Parkinsons trials. A lot of questions regarding our understanding of that 'sub-type' will be answered by those trials. But while those trials play out (with significant support from groups like @silversteinFNDN..
Proud to announce the launch of #ChamishiTherapeutics in collaboration with @QStateBio #CureGBA #Chamishi #ASOs #antisense #CureParkinsons silversteinfoundation.org/20…